HHS leadership has announced they will be pursuing steps to “crack down on fraud in Medicare and Medicaid.”
TrumpRx, a direct-to-consumer drug purchasing platform, limited to self-pay patients, is live, as of Feb. 5.
Trump administration announces “major crackdown” on healthcare fraud
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Dana-Farber Cancer Institute has agreed to pay $15 million to the U.S. government in a settlement to resolve allegations that, between 2014 and 2024, Dana-Farber violated the False Claims Act by “using fraudulent images in grant applications and research articles to induce the NIH to pay millions of dollars to support research at Dana-Farber.”
Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, said he was named chair of the President’s Cancer Panel. Risch will succeed Elizabeth M. Jaffee, who was appointed by President Joe Biden in January 2023.
In a Dec. 5 memo, President Donald Trump directed the HHS secretary and the CDC director to “align the U.S. core childhood vaccine recommendations with best practices from peer, developed countries.”
The “One Big Beautiful Bill Act” includes new restrictions on federal student loan borrowing that the Trump administration says are aimed at driving down the cost of graduate education. However, critics of the change say that the reduced access to low-interest federal loans will further reduce the accessibility of graduate and professional degrees.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
